Literature DB >> 17065370

An Official ATS Workshop Summary: Recent advances and future directions in pneumocystis pneumonia (PCP).

Laurence Huang, Alison Morris, Andrew H Limper, James M Beck.   

Abstract

Pneumocystis pneumonia (PCP) is a major cause of morbidity and mortality among immunocompromised persons, and it remains a leading acquired immune deficiency syndrome (AIDS)-defining opportunistic infection in human immunodeficiency virus (HIV)-infected individuals throughout the world. Pneumocystis has proven difficult to study, in part due to the lack of a reliable culture system for the organism. With the development of molecular techniques, significant advances in our understanding of the organism and the disease have been made over the past several years. These advances include an improved understanding of host-organism interactions and host defense, the development of noninvasive polymerase chain reaction (PCR)-based diagnostic assays, and the emerging data regarding the possible development of trimethoprim-sulfamethoxazole-resistant Pneumocystis. In addition, the recognition that patients without PCP may nevertheless be carriers of or colonized with Pneumocystis, and observations that suggest a role for Pneumocystis in the progression of pulmonary disease, combine to signal the need for a comprehensive and accessible review. In May 2005, the American Thoracic Society sponsored a one-day workshop, "Recent Advances and Future Directions in Pneumocystis Pneumonia (PCP)," which brought together 45 Pneumocystis researchers. The workshop included 21 presentations on diverse topics, which are summarized in this report. The workshop participants identified priorities for future research, which are summarized in this document.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17065370     DOI: 10.1513/pats.200602-015MS

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  32 in total

Review 1.  Update on the diagnosis and treatment of Pneumocystis pneumonia.

Authors:  Eva M Carmona; Andrew H Limper
Journal:  Ther Adv Respir Dis       Date:  2010-08-24       Impact factor: 4.031

2.  High prevalence of dihydropteroate synthase mutations in Pneumocystis jirovecii isolated from patients with Pneumocystis pneumonia in South Africa.

Authors:  Leigh Dini; Mignon du Plessis; John Frean; Victor Fernandez
Journal:  J Clin Microbiol       Date:  2010-03-29       Impact factor: 5.948

3.  Serum (1->3)-{beta}-D-Glucan assay for the diagnosis of Pneumocystis jiroveci pneumonia.

Authors:  Amalia Del Palacio; Maria Soledad Cuétara; Jara Llenas-García; Maria Elena Alvarez; Fernando Chaves; Federico Pulido; Mercedes Catalán; José Pontón; Valerio Del Bono; Claudio Viscoli
Journal:  Clin Vaccine Immunol       Date:  2010-01

4.  Trimethoprim-sulfamethoxazole treatment does not reverse obstructive pulmonary changes in pneumocystis-colonized nonhuman primates with SHIV infection.

Authors:  Heather M Kling; Timothy W Shipley; Siobhan Guyach; Rebecca Tarantelli; Alison Morris; Karen A Norris
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

5.  The Pneumocystis Ace2 transcription factor regulates cell wall-remodeling genes and organism virulence.

Authors:  Theodore J Kottom; Andrew H Limper
Journal:  J Biol Chem       Date:  2013-06-25       Impact factor: 5.157

6.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

7.  Evidence for Proinflammatory β-1,6 Glucans in the Pneumocystis carinii Cell Wall.

Authors:  Theodore J Kottom; Deanne M Hebrink; Paige E Jenson; Gunnar Gudmundsson; Andrew H Limper
Journal:  Infect Immun       Date:  2015-04-27       Impact factor: 3.441

8.  Characterization of PCEng2, a {beta}-1,3-endoglucanase homolog in Pneumocystis carinii with activity in cell wall regulation.

Authors:  Leah R Villegas; Theodore J Kottom; Andrew H Limper
Journal:  Am J Respir Cell Mol Biol       Date:  2009-09-25       Impact factor: 6.914

9.  Characterization of a novel ADAM protease expressed by Pneumocystis carinii.

Authors:  Cassie C Kennedy; Theodore J Kottom; Andrew H Limper
Journal:  Infect Immun       Date:  2009-05-18       Impact factor: 3.441

10.  Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: a prospective study.

Authors:  Yasuo Shimizu; Noriaki Sunaga; Kunio Dobashi; Makoto Fueki; Naoto Fueki; Sohei Makino; Masatomo Mori
Journal:  BMC Infect Dis       Date:  2009-04-22       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.